Abstract:Our immune system has evolved to detect and eradicate threats with unique specificity and efficiency. It thus can become one of the most potent allies in medicine, if it can be properly utilized and instructed. Modern approaches in precision immunotherapy do exactly that. Immunotherapies continue to be a gamechanger when it comes to treating severe, sometimes previously untreatable diseases, in particular cancer. This Highlight Issue on Immunoengineering sheds light on some recent and future developments in this rapidly developing field. A review by Schoenfeld et al. (2024) summarizes recent developments in the field on dual-targeting antibody (and cell) therapies. Simultaneously targeting two antigens at the same time is more and more used in the clinics to avoid side effects of antibody therapies by increasing specificity – but also to connect certain target structures to obtain desired biological outcomes (e.g. by recruiting T cells to cancer cells). Antibody therapies, the mainstay of current precision immunotherapies, are thus currently entering the next stages driven by molecular engineering. This development is also highlighted in a research article by Arras et al. (2024) which shows that naturally occurring antibodies with ultralong, antigen-binding complementarity-determining regions (CDRs) can inspire the engineering of chimeric antibodies with optimized binding properties, an approach which may also prove to be very relevant for targeting cryptic antigens. Although antibodies are continuously refined and optimized, biologicals beyond antibodies also need to be considered for immunotherapy, as they can make completely new modes of action available to patients. One example are cytokines, that can e.g. be used to control immune reactions in desired ways or to arm engineered cells in cell-based therapies. The production of non-antibody biologicals, however, is often a bottleneck in their development and thus hampers medical progress. A research article by Aschenbrenner et al. (2024) in this issue presents a new platform biotechnology for the production of non-antibody biologicals while also optimizing their biophysical characteristics. Such a technique may prove crucial for next-generation immunotherapeutics beyond antibodies. Beyond antibodies, one further very important and rapidly progressing development in the field of immunotherapies is the engineering of immune cells as advanced therapeutic modalities. For the first time, these so-called living drugs are entering the clinics. The first generation of these living drugs are engineered T cells with chimeric antigen receptors (CAR T cells). Tsiverioti et al. (2024) review developments beyond CAR T cells, e.g. engineered natural killer and macrophages, building on the CAR technology first developed for T cells. The time of these new approaches in the clinics is mostly yet to come, but very likely to do so because of the unique advantages certain cell types have may have over T cells in several disease settings. A research article by Carr et al. (2024) sheds light on a different possible approach in cell-based therapies, using T cells and T cell receptors with desired targeting properties to combat e.g. viral diseases and cancer. Here, the selection of the best TCRs is crucial. To achieve this directly in a cellular context, the authors developed a high-throughput capable cell-avidity based approach. This work holds great promise to accelerate the workflow of TCR selection, directly in a cellular context, and thus will accelerate the development of T cells as living drugs. A further angle on cell engineering comes from a research article by Baumgärtner et al. (2024). The authors show that disulfide bond formation in the transmembrane regions of cytokine receptors can drive their ligand-independent signaling. This can be a cause of disease, as observed in e.g. leukemia, but could potentially also be exploited in cell engineering to equip cells with strong and permanent activation and persistence signals which they need to act in the often immune-suppressive tumor microenvironment. Indeed, the authors show that the motif they identify to be relevant for autonomous receptor activation is transplantable into cytokine receptors beyond its origin. Current developments in the field, from next-generation antibody therapies, via immunotherapeutics beyond antibodies to cell-based therapies are thus covered in this highlight issue. In this rapidly developing field, very often complementary expertise is needed to engineer the most efficient and safest next generation immunotherapies. A prime example of such a joint effort with a common goal is the DFG-funded CRC LETSimmun (Lymphocyte Engineering for Therapeutic Synthetic Immunity, https://letsimmun.de/). A further ingredient to success, in this case meaning that novel immunotherapies become accessible to patients, is that academic and industrial research -Abstract Truncated-

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

Development of Therapeutic Proteins: Advances and Challenges

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

Immunogenicity assessment strategy for a chemically modified therapeutic protein in clinical development

Highlight: new developments in immunoengineering

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies

Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications

Prospects for the computational humanization of antibodies and nanobodies

Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis

Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies